News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Teva Pharmaceutical Industries Limited (TEVA) Reaches Settlement In ProAir® HFA Patent Case


6/20/2014 9:33:23 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced that it has reached a settlement with Perrigo Pharmaceutical Co. and Catalent Pharma Solutions LLC with respect to four patents for Teva’s ProAir® HFA (albuterol sulfate) Inhalation Aerosol product. This settlement provides a license to Perrigo and Catalent to sell limited units of Perrigo’s generic version of the product for an initial period beginning Dec. 19, 2016 and lasting until June 2018, when the limits will no longer apply.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES